Nature Communications (Sep 2022)

Identification of a cross-neutralizing antibody that targets the receptor binding site of H1N1 and H5N1 influenza viruses

  • Tingting Li,
  • Junyu Chen,
  • Qingbing Zheng,
  • Wenhui Xue,
  • Limin Zhang,
  • Rui Rong,
  • Sibo Zhang,
  • Qian Wang,
  • Minqing Hong,
  • Yuyun Zhang,
  • Lingyan Cui,
  • Maozhou He,
  • Zhen Lu,
  • Zhenyong Zhang,
  • Xin Chi,
  • Jinjin Li,
  • Yang Huang,
  • Hong Wang,
  • Jixian Tang,
  • Dong Ying,
  • Lizhi Zhou,
  • Yingbin Wang,
  • Hai Yu,
  • Jun Zhang,
  • Ying Gu,
  • Yixin Chen,
  • Shaowei Li,
  • Ningshao Xia

DOI
https://doi.org/10.1038/s41467-022-32926-5
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 17

Abstract

Read online

Circulating subtypes of Influenza viruses seasonally change and therefore vaccines need to be matched to these strains each year, which is why there is a need for next-generation vaccines that can elicit broad and cross-type protection. Here, Li et al. generate a human-mouse chimeric antibody with broad neutralizing activity against seasonal and pandemic H1N1 and some H5N1 viruses in vivo and identify residues on hemagglutinin relevant for its broad neutralization activity.